Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · April 22, 2024

Effectiveness of Early Use of Erenumab vs Nonspecific Oral Migraine Preventives

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial
JAMA Neurol 2024 Mar 25;[EPub Ahead of Print], P Pozo-Rosich, D Dolezil, K Paemeleire, A Stepien, P Stude, J Snellman, M Arkuszewski, T Stites, S Ritter, CL Lopez, J Maca, M Ferraris, R Gil-Gouveia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading